Melinta Therapeutics, a commercial-stage pharmaceutical company based in New Jersey, specializes in the discovery, development, and commercialization of antibiotics targeting bacterial infections. The company's product portfolio includes Baxdela, Vabomere, Orbactiv, and Minocin, which are designed to treat various bacterial infections, particularly acute bacterial skin and skin structure infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is in Phase 3 development, and is dedicated to creating new classes of antibiotics to address the growing challenge of drug-resistant infections, particularly those caused by ESKAPE pathogens. The company has established partnerships with several institutions, including Yale University and Wakunaga Pharmaceutical Co., Ltd., to enhance its research and development efforts. As the need for effective treatments for resistant infections becomes increasingly urgent, Melinta Therapeutics is committed to providing innovative solutions in the field of anti-infectives.
Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel antibiotics to combat serious multidrug-resistant infections. Its primary product candidate, Xerava (eravacycline), is a synthetic fluorocycline designed for intravenous use as a first-line treatment for multidrug-resistant infections, particularly those caused by Gram-negative bacteria. The company has conducted Phase III clinical trials, including IGNITE1 and IGNITE4, to evaluate Xerava's safety and efficacy for treating complicated intra-abdominal infections. In addition to Xerava, Tetraphase is advancing other product candidates, such as TP-271, which targets respiratory diseases caused by antibiotic-resistant pathogens, and TP-6076, aimed at treating multidrug-resistant Gram-negative infections. The company holds a licensing agreement with Everest Medicines Limited to develop and commercialize Xerava in various Asian markets. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase Pharmaceuticals is a subsidiary of La Jolla Pharmaceutical Company.
The Medicines Company - Infectious Disease Care
Acquisition in 2017
The Medicines Company - Infectious Disease Care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.